| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Richard Newcomb Stillwell is Director at TNXP. Richard Newcomb Stillwell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $26K at current prices.
Net of sales, the TNXP filings show accumulation of 5,000 shares.
Richard Newcomb Stillwell has 6 Form 4 filings on record from March 2023 to June 2026, all as Director at Tonix Pharmaceuticals (TNXP), 2023–2026.
The 6 reported transactions were 5 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $58K and no sales.
The only open-market purchase was 5,000 shares of TNXP at an average $11.65 on June 8, 2026, about $58K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 5,000 | $11.65 | $58,250.00 | New | +12.4% | - |